论文部分内容阅读
Objective:The aim of this study was to investigate the ef ect of toremifene on A549 human lung adenocarci-noma cells, and its sensibilization with gemcitabine, so that to provide a new clinical approach for non-smal-celllung cancer (NSCLC). Methods:A549 cells were seeded into 96-wel plates and exposed to dif erent agents (gemcitabine or gemcitabine with toremifene). The cytotoxicity of each agent was evaluated by MTT, cellcycle and apoptotic rate were detected by flow cytometry (FCM). Results:1. By using FCM, we found A549 cells in S and G2/M phases with toremifene decreased but increased in G0/G1 phase. The higher concentration of toremifene, the more decreased was when compared with the control group. 2. FCM showed toremifene’s apoptosis ef ect on A549 cells increased with its increasing dose. 3. By MTT, toremifene had no cytotoxic ef ect on A549 cells at the concentration of 5 or 2.5 μmol/L. The IC50 of gemcitabine to A549 was 34.51 μmol/L, and the combined group was 13.59 μmol/L. Conclusion:Toremifene could inhibit the growth of A549 human lung adenocarcinoma cells. Toremifene combined with gemcitabine showed significantly remarkable chemotherapy sensibilization on A549 human lung adenocarcinoma cells.